About: Novel Insights Into Illness Progression and Risk Profiles for Mortality in Non-survivors of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Novel Insights Into Illness Progression and Risk Profiles for Mortality in Non-survivors of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Novel Insights Into Illness Progression and Risk Profiles for Mortality in Non-survivors of COVID-19
Creator	Liu, Yu Chen, Yongwen Zhou, Yi Wang, Xinghuan Liu, Y Kozlakidis, Zisis Zhou, Fuling Liu, Yanan Liu, Minghui Shao, Liang Li, Xinyi Yu, Yalan Zahran, Asmaa Zhang, Haojian Zhang, Ruixian
Source	Medline; PMC
abstract	Background. The outbreak of COVID-19 has attracted the attention of the whole world. Our study aimed to describe illness progression and risk profiles for mortality in non-survivors. Methods. We retrospectively analyzed 155 patients with COVID-19 in Wuhan and focused on 18 non-survivors among them. Briefly, we compared the dynamic profile of biochemical and immune parameters and drew an epidemiological and clinical picture of disease progression from disease onset to death in non-survivors. The survival status of the cohort was indicated by a Kaplan–Meier curve. Results. Of the non-survivors, the median age was 73.5 years, and the proportion of males was 72.2%. Five and 13 patients were hospital-acquired and community-acquired infection of SARS-CoV-2, respectively. The interval between disease onset and diagnosis was 8.5 days (IQR, [4–11]). With the deterioration of disease, most patients experienced consecutive changes in biochemical parameters, including lymphopenia, leukocytosis, thrombocytopenia, hypoproteinemia, as well as elevated D-dimer and procalcitonin. Regarding the immune dysregulation, patients exhibited significantly decreased T lymphocytes in the peripheral blood, including CD3(+)T, CD3(+)CD4(+)Th, and CD3(+)CD8(+)Tc cells. By the end of the disease, most patients suffered from severe complications, including ARDS (17/18; 94.4%), acute cardiac injury (10/18; 55.6%), acute kidney injury (7/18; 38.9%), shock (6/18; 33.3%), gastrointestinal bleeding (1/18; 5.6%), as well as perforation of intestine (1/18; 5.6%). All patients died within 45 days after the initial hospital admission with a median survivor time of 13.5 days (IQR, 8–17). Conclusions. Our data show that patients experienced consecutive changes in biochemical and immune parameters with the deterioration of the disease, indicating the necessity of early intervention.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.3389/fmed.2020.00246
bibo:pmid	32574334
has license	cc-by
sha1sum (hex)	ed9770c6959384ce23438baf3f751ecaf26deef9
schema:url	https://doi.org/10.3389/fmed.2020.00246
resource representing a document's title	Novel Insights Into Illness Progression and Risk Profiles for Mortality in Non-survivors of COVID-19
has PubMed Central identifier	PMC7256183
has PubMed identifier	32574334
schema:publication	Front Med (Lausanne)
resource representing a document's body	covid:ed9770c6959384ce23438baf3f751ecaf26deef9#body_text
is schema:about of	named entity '20%' named entity 'neutrophil' named entity 'infection' named entity 'cough' named entity 'red blood cells' named entity 'Prothrombin time' named entity 'procalcitonin' named entity 'normal distribution' named entity 'ritonavir' named entity 'cohort study' named entity 'albumin' named entity 'respiratory frequency' named entity 'electrolyte disturbance' named entity 'ECMO' named entity 'diarrhea' named entity 'Epidemiological' named entity 'platelet' named entity 'Wuhan University' named entity 'Wuhan University' named entity 'multiple organ dysfunction' named entity 'epidemic' named entity 'clinical symptoms' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'fever' named entity 'drug resistance' named entity 'rescue therapy' named entity 'COVID' named entity 'cTnI' named entity 'Nucleic Acid' named entity 'prothrombin time' named entity 'CD3' named entity 'nutrition' named entity 'WBC' named entity 'albumin' named entity 'prothrombin time' named entity 'myocardial injury' named entity 'mycoplasma' named entity 'CD3' named entity 'COVID' named entity 'immune systems' named entity 'tigecycline' named entity 'viruses' named entity 'renal diseases' named entity 'linezolid' named entity 'infection' named entity 'COVID-19' named entity 'dry cough' named entity 'Klebsiella' named entity 'CRRT' named entity 'nucleic acid test' named entity 'clinical characteristics' named entity 'SARS-CoV-2' named entity 'chronic obstructive pulmonary diseases' named entity 'COVID' named entity 'multiple organ dysfunction' named entity 'epidemic' named entity 'hospital-acquired infection' named entity 'hematological' named entity 'hepatitis' named entity 'informed consent' named entity 'platelet count' named entity 'positively correlated' named entity 'respiratory failure' named entity 'CD3' named entity 'critically ill' named entity 'WBC'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software